IBOV 172,060.43 ▲ 0.42% IPC MEX 72,006.05 ▲ 0.16% MERVAL 2,848,945 — — USD/BRL5.59▲ 0.09% USD/MXN18.61▲ 0.03% USD/CLP982.08▼ 0.22% USD/COP3,279▼ 0.85% USD/PEN3.41▼ 0.02% USD/ARS1,544▼ 0.03% USD/UYU40.52▲ 3.70% USD/PYG6,174▲ 3.14% USD/BOB11.63▲ 1.12% USD/DOP60.48▲ 0.05% USD/CRC446.01▲ 1.79% USD/GTQ7.64▲ 3.16% USD/HNL26.90▲ 3.29% USD/NIO36.62▲ 2.73% USD/VES902.19▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.49▲ 2.41% USD/TTD6.72▲ 2.22% EUR/BRL6.19▼ 0.58% BRENT 93.28 ▲ 0.56% WTI 86.90 ▲ 0.43% IRON ORE 161.91 — — COPPER 6.21 ▼ 0.96% GOLD 3,966 ▼ 0.87% SILVER 51.11 ▼ 1.50% SOY 1,226 ▼ 0.22% CORN 448.00 — 0.00% WHEAT 600.00 ▲ 0.08% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20% IBOV 172,060.43 ▲ 0.42% IPC MEX 72,006.05 ▲ 0.16% MERVAL 2,848,945 — — USD/BRL 5.58 ▲ 0.00% USD/MXN 18.63 ▲ 0.14% USD/CLP 982.08 ▼ 0.22% USD/COP 3,279 ▼ 0.85% USD/PEN 3.41 ▼ 0.02% USD/ARS 1,544 ▼ 0.03% USD/UYU 40.52 ▲ 3.32% USD/PYG 6,174 ▲ 3.14% USD/BOB 11.63 ▲ 0.92% USD/DOP 60.48 ▲ 0.05% USD/CRC 446.01 ▲ 1.79% USD/GTQ 7.64 ▲ 3.16% USD/HNL 26.90 ▲ 3.29% USD/NIO 36.62 ▲ 2.73% USD/VES 902.19 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.49 ▲ 2.41% USD/TTD 6.72 ▲ 2.22% EUR/BRL 6.18 ▼ 0.75% BRENT 93.28 ▲ 0.56% WTI 86.90 ▲ 0.43% IRON ORE 161.91 — — COPPER 6.21 ▼ 0.96% GOLD 3,966 ▼ 0.87% SILVER 51.11 ▼ 1.50% SOY 1,226 ▼ 0.22% CORN 448.00 — 0.00% WHEAT 600.00 ▲ 0.08% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20%
since 2009
Thursday, November 12, 2026

Covid-19 Brazil

Sinovac vaccine may not trigger sufficient antibody response to Brazil variant: study

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Sinovac Biotech’s COVID-19 vaccine may not trigger sufficient antibody responses against a new variant identified in Brazil, a small-sample lab study showed.

The emergence of variants of the new coronavirus has raised concern that vaccines and treatments that were developed based on previous strains may not work as robustly.

In this photo illustration a medical syringe seen with
Sinovac vaccine may not trigger sufficient antibody response to Brazil variant. Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Plasma samples taken from eight people vaccinated with Sinovac’s CoronaVac failed to efficiently neutralize the P.1 lineage variant, or 20J/501Y.V3, researchers said in a paper published on Monday ahead of peer-review.

“These results suggest that P.1 virus might escape from neutralizing antibodies induced by… CoronaVac,” researchers at the University of São Paulo in Brazil, Washington University School of Medicine in the United States, and a few other institutions said in the paper.

CoronaVac is being used in mass vaccination drives in countries including China, Brazil, Indonesia and Turkey.

Although the study suggests re-infection may occur in vaccinated individuals, the protection given by CoronaVac against severe COVID-19 may indicate that other mechanisms in the human immune system, aside from antibodies, contribute to reducing disease severity, researchers said.

A Sinovac spokesman was not immediately available for comment. Chief executive Yin Weidong said in a program aired by state-backed broadcaster CGTN on Thursday the company is “fully capable” of using current research and manufacturing capacity to develop a new vaccine against variants if necessary.

He also said the process would take much less time than it took to develop CoronaVac.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.